In a significant development for proponents of peptide therapies and for those advocating for greater access to experimental treatments, an advisory panel to the Food and Drug Administration (FDA) recommended on Thursday that compounding pharmacies be permitted to manufacture the drugs BPC-157 and KPV. This recommendation, if ultimately adopted by the FDA, would represent a notable shift in the regulatory landscape surrounding these largely unproven yet increasingly popular compounds....
